Amyloidosis: Graviores morbos, asperis remedii

Abstract

In this issue of Blood, Sanchorawala and colleagues provide 10-year follow-up of their efforts to treat immunoglobulin light chain (AL) amyloidosis with high-dose melphalan in the 1990s. They report median survival durations approaching 5 years for all patients and exceeding 10 years for those attaining hematologic complete remission.